Table 1.
Patients and treatment characteristics
| Characteristics of 172 Patients | ||
|---|---|---|
| No | % | |
| Age (years) | ||
| Median (range) | 73 (54–92) | |
| Sex | ||
| Male | 100 | 58 |
| Female | 72 | 42 |
| T stage | ||
| IA (T1a-c) | 110 | 64 |
| IB (T2a) | 39 | 23 |
| IIA (T2b) | 23 | 13 |
| Pathologic confirmation | ||
| Yes ( spino/adeno) | 82 (44/70) | 48 |
| No | 90 | 52 |
| PET | ||
| Yes | 105 | 61 |
| No | 67 | 39 |
| COPD (GOLD) | ||
| 0 | 43 | 25 |
| 1 | 23 | 13 |
| 2 | 42 | 24 |
| 3 | 37 | 22 |
| 4 | 27 | 16 |
| FEV1% predicted | ||
| Median (range) | 55% (20–137) | |
| ≥ 50% | 108 | 63 |
| < 50% | 64 | 37 |
| AACCI | ||
| Median (range) | 5 points (2-10) | |
| 2–5 | 114 | 66 |
| 6–10 | 58 | 34 |
| Performance Status | ||
| 0 | 45 | 26 |
| 1 | 88 | 51 |
| 2 | 39 | 23 |
| Tumor location | ||
| Central | 23 | 13 |
| Peripheral | 149 | 87 |
| Dose fractionation | ||
| 60–54 Gy/3fr. | 92 | 53 |
| 30–33 Gy/1fr. | 19 | 11 |
| 60–55 Gy/5fr. | 42 | 24 |
| 50 Gy/5fr. | 19 | 11 |
| BED 10 prescribed | ||
| Median (range) | 151.2 (94–180) | |
| ≥ 151.2 Gy | 82 | 48 |
| < 151.2 Gy | 90 | 52 |
| BED 10 maximum | ||
| Median (range) | 251.6 (135–398) | |
| ≥ 251.6 Gy | 75 | 44 |
| < 251.6 Gy | 97 | 56 |
For continuous variables, the median and range are given; for categorical variables, the number of patients and percentages are given, AACCI: age-adjusted Charlson comorbidity index; CHOPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; FEV1: forced expiratory volume in 1 s; BED10 biologically effective dose with alpha/beta = 10 Gy